The stock of Kazia Therapeutics Limited ADR (KZIA) has gone up by 5.99% for the week, with a -19.81% drop in the past month and a 57.70% rise in the past quarter. The volatility ratio for the week is 6.48%, and the volatility levels for the past 30 days are 10.64% for KZIA. The simple moving average for the past 20 days is -2.57% for KZIA’s stock, with a 3.63% simple moving average for the past 200 days.
Is It Worth Investing in Kazia Therapeutics Limited ADR (NASDAQ: KZIA) Right Now?
Moreover, the 36-month beta value for KZIA is 2.11. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for KZIA is 23.62M and currently, short sellers hold a 6.79% of that float. On September 26, 2024, KZIA’s average trading volume was 13.12M shares.
KZIA) stock’s latest price update
The stock of Kazia Therapeutics Limited ADR (NASDAQ: KZIA) has increased by 7.06 when compared to last closing price of 0.33. Despite this, the company has experienced a 5.99% gain in its stock price over the last five trading sessions. prnewswire.com reported 2024-09-23 that SYDNEY, Sept. 23, 2024 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the presentation of data highlighting promising clinical activity of EVT801 in high grade serous (HGS) Ovarian Cancer at the 15th Biennial Ovarian Cancer Research Symposium, co-presented by American Association of Cancer Research (AACR) and the Rivkin Center for Ovarian Cancer Research on Saturday, September 21, 2024 in Seattle Washington.
Analysts’ Opinion of KZIA
Many brokerage firms have already submitted their reports for KZIA stocks, with Maxim Group repeating the rating for KZIA by listing it as a “Buy.” The predicted price for KZIA in the upcoming period, according to Maxim Group is $18 based on the research report published on October 14, 2021 of the previous year 2021.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see KZIA reach a price target of $17. The rating they have provided for KZIA stocks is “Buy” according to the report published on January 05th, 2021.
KZIA Trading at -8.76% from the 50-Day Moving Average
After a stumble in the market that brought KZIA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.84% of loss for the given period.
Volatility was left at 10.64%, however, over the last 30 days, the volatility rate increased by 6.48%, as shares sank -10.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -47.01% lower at present.
During the last 5 trading sessions, KZIA rose by +5.66%, which changed the moving average for the period of 200-days by -12.75% in comparison to the 20-day moving average, which settled at $0.3574. In addition, Kazia Therapeutics Limited ADR saw -20.34% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for KZIA
Current profitability levels for the company are sitting at:
- -34631.15 for the present operating margin
- 1.0 for the gross margin
The net margin for Kazia Therapeutics Limited ADR stands at -28040.47. The total capital return value is set at -1.49. Equity return is now at value -181.74, with -58.59 for asset returns.
Based on Kazia Therapeutics Limited ADR (KZIA), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -35.3.
Currently, EBITDA for the company is -22.28 million with net debt to EBITDA at 0.18. When we switch over and look at the enterprise to sales, we see a ratio of 21457.24. The receivables turnover for the company is 0.01for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.71.
Conclusion
To wrap up, the performance of Kazia Therapeutics Limited ADR (KZIA) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
